<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294826</url>
  </required_header>
  <id_info>
    <org_study_id>CAUY922AUS06T</org_study_id>
    <nct_id>NCT01294826</nct_id>
  </id_info>
  <brief_title>Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with
      cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>1 cycle (1 cycle = 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient response rate to the AUY922.</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression following treatment with AUY922.</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients treated with AUY922.</measure>
    <time_frame>After 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <arm_group>
    <arm_group_label>AUY922 plus Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUY922</intervention_name>
    <description>Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.</description>
    <arm_group_label>AUY922 plus Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.</description>
    <arm_group_label>AUY922 plus Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed colorectal cancer

          -  KRAS wild type metastatic colorectal cancer

          -  Progression of disease on at least 2 prior therapy to have included 5FU, or
             oxaliplatin or bevacizumab or irinotecan

          -  Prior treatment with cetuximab is allowed (full dose tolerated), provided that the
             patient never required a dose reduction due to toxicities

          -  Must have at least one measurable lesion

          -  Must be 18 years of age or older

          -  ECOG performance status 0-1

          -  Life expectancy must be greater than 12 weeks

          -  For women of childbearing potential, a negative pregnancy blood test must be obtained
             less than 3 days prior to the first AUY922 infusion

        Exclusion Criteria:

          -  Colorectal cancer with a KRAS mutation or in which the KRAS genotype status is unknown

          -  Metastasis to the CNS

          -  Prior treatment with any Hsp90 inhibitor compounds

          -  Patients who received systemic anti-cancer treatment prior to the first dose of AUY922
             within the following time frames:

               -  Radiotherapy, conventional chemotherapy: within 2 weeks

               -  Palliative radiotherapy: within 2 weeks

               -  Nitrosoureas, monoclonal antibodies, such as trastuzumab and mitomycin: within 6
                  weeks

               -  Any continuous-dosing (i.e. daily dosing, every-other-day dosing,
                  Monday-Wednesday-Friday dosing, weekly etc.) of systemic anti-cancer treatment
                  for which the recover period is not known, or investigational drugs (i.e.
                  targeted agents) within a duration of ≤ 5 half lives of the agent and their
                  active metabolites (if any)

          -  Treatment of therapeutic doses of coumadin-type anticoagulants. [Maximum daily dose of
             2mg, for line patency permitted]

          -  Known sensitivity to cetuximab

          -  Unresolved ≥ grade 1 diarrhea

          -  Malignant ascites that require invasive treatment

          -  Concurrent medications that are substrates, inhibitors or inducers of CYP3A4, CYP2C8,
             CYP2C9 and CYP2C19 and cannot be switched or discontinued or switched to an
             alternative drug prior to commencing AUY922 dosing need special consideration on a
             case by case basis

          -  Major surgery ≤ 2 weeks prior to randomization or who have not recovered from such
             therapy

          -  Impaired cardiac function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swedish Medical Center Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Rectal Diseases</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>HSP90 Heat-Shock Proteins</keyword>
  <keyword>EGFR protein, human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

